Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Size to Expand Significantly USD 4476.99 Million By 2030
11 mai 2022 16h00 HE
|
Fior Markets
Newark, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by MRInsights.biz, the global Bruton tyrosine kinase (BTK) inhibitors market is expected to grow from USD 2,695.35 million in...
Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia
05 janv. 2022 09h00 HE
|
Oncolyze Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncolyze, Inc, a biotech developing a disruptive technology for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
16 déc. 2021 07h00 HE
|
IN8bio, Inc
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to...
Global Acute Lymphoblastic Leukemia Treatment Market Report 2021-2026: Opportunities with Limited Players in the Market & Increasing Investment in R&D of Different Leukemia Treatments
14 déc. 2021 05h48 HE
|
Research and Markets
Dublin, Dec. 14, 2021 (GLOBE NEWSWIRE) -- The "Global Acute Lymphoblastic Leukemia Treatment Market (2021-2026) by Type, Types of Cell, Therapy, Geography, Competitive Analysis and the Impact of...
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
05 nov. 2021 05h58 HE
|
Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
04 oct. 2021 07h00 HE
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
AB Science a reçu l’approbation de l’autorité de santé canadienne pour initier une étude de Phase I/II avec sa molécule AB8939 dans le traitement de la leucémie myéloïde aiguë (LMA)
22 sept. 2021 12h09 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE L’AUTORITE DE SANTÉ CANADIENNE POUR INITIER UNE ÉTUDE DE PHASE I/II AVEC SA MOLÉCULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË...
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
22 sept. 2021 12h09 HE
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC...
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
16 août 2021 19h55 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
Global Chronic Lymphocytic Leukemia (CLL) Disorder Clinical Market Report 2021-2027
06 juil. 2021 08h08 HE
|
Research and Markets
Dublin, July 06, 2021 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering. Chronic lymphocytic leukemia (CLL) is a disorder where...